Sildenafil treats persistent pulmonary hypertension of the newborn (PPHN) by selectively inhibiting phosphodiesterase type 5 (PDE5). This inhibition leads to increased levels of cyclic guanosine monophosphate (cGMP).
Elevated cGMP and Vascular Effects
Higher cGMP levels relax pulmonary vascular smooth muscle. This vasodilation reduces pulmonary vascular resistance, improving blood flow to the lungs and increasing oxygenation.
Improved Oxygenation and Reduced Pulmonary Pressure
The improved blood flow translates to better oxygen levels in the infant’s blood. Consequently, pulmonary arterial pressure decreases, relieving strain on the heart.
Dosage Considerations and Monitoring
Precise sildenafil dosing for PPHN is determined by the infant’s weight and clinical response. Careful monitoring of blood pressure, oxygen saturation, and other vital signs is crucial.
Potential Side Effects
| Hypotension | Possible |
| Apnea | Possible |
| Retinopathy | Rare |
Further Research and Clinical Applications
Ongoing research explores sildenafil’s role in combination therapies for PPHN and in specific patient subgroups. Clinicians carefully evaluate individual patient characteristics to optimize treatment.
